Keywords:
Allergic rhinitis; asthma; backache; chronic sinusitis; coronavirus 2019; coughing; nose obstruction; retrospective study; sanger sequencing
Abstract:
Ensitrelvir, a 3C-like protease inhibitor, received emergency approval in Japan in November 2022 for treating non-hospitalized patients with mild-to-moderate COVID-19. However, confirmation of its real-world clinical effectiveness is limited.